Regeneron Pharmaceuticals (REGN) Downgraded by BidaskClub to “Hold”

BidaskClub lowered shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a buy rating to a hold rating in a report released on Wednesday.

A number of other analysts have also weighed in on the stock. Cowen reissued a hold rating and issued a $385.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, October 22nd. Cantor Fitzgerald increased their price objective on shares of Regeneron Pharmaceuticals to $441.00 and gave the stock a neutral rating in a research report on Monday, October 22nd. JPMorgan Chase & Co. set a $405.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a hold rating in a research report on Monday, October 22nd. Morgan Stanley increased their price objective on shares of Regeneron Pharmaceuticals from $409.00 to $412.00 and gave the stock an equal weight rating in a research report on Thursday, October 11th. Finally, Canaccord Genuity raised their target price on shares of Regeneron Pharmaceuticals from $390.00 to $410.00 and gave the stock a hold rating in a research report on Thursday, October 11th. Two research analysts have rated the stock with a sell rating, seventeen have given a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus price target of $410.95.

Regeneron Pharmaceuticals stock traded down $2.52 during midday trading on Wednesday, reaching $352.59. The stock had a trading volume of 662,514 shares, compared to its average volume of 824,728. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.62 and a quick ratio of 2.92. Regeneron Pharmaceuticals has a 52-week low of $281.89 and a 52-week high of $432.50. The firm has a market capitalization of $38.10 billion, a P/E ratio of 21.42, a price-to-earnings-growth ratio of 1.18 and a beta of 1.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported $5.45 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.60 by $0.85. Regeneron Pharmaceuticals had a net margin of 25.65% and a return on equity of 29.30%. The company had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same period in the prior year, the company posted $4.17 EPS. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. Research analysts anticipate that Regeneron Pharmaceuticals will post 19.31 earnings per share for the current fiscal year.

In other news, Director Michael S. Brown sold 2,000 shares of the stock in a transaction that occurred on Thursday, September 27th. The shares were sold at an average price of $392.26, for a total transaction of $784,520.00. Following the transaction, the director now directly owns 2,000 shares in the company, valued at $784,520. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Michael S. Brown sold 1,500 shares of the stock in a transaction that occurred on Wednesday, August 22nd. The shares were sold at an average price of $380.49, for a total transaction of $570,735.00. Following the transaction, the director now owns 1,500 shares in the company, valued at $570,735. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 110,052 shares of company stock worth $44,651,762. Corporate insiders own 12.42% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mn Services Vermogensbeheer B.V. boosted its stake in shares of Regeneron Pharmaceuticals by 2.4% during the third quarter. Mn Services Vermogensbeheer B.V. now owns 12,772 shares of the biopharmaceutical company’s stock valued at $5,160,000 after purchasing an additional 300 shares in the last quarter. BP PLC boosted its stake in shares of Regeneron Pharmaceuticals by 11.1% during the third quarter. BP PLC now owns 10,000 shares of the biopharmaceutical company’s stock valued at $4,040,000 after purchasing an additional 1,000 shares in the last quarter. Virginia Retirement Systems ET AL boosted its stake in shares of Regeneron Pharmaceuticals by 39.8% during the third quarter. Virginia Retirement Systems ET AL now owns 50,900 shares of the biopharmaceutical company’s stock valued at $20,566,000 after purchasing an additional 14,500 shares in the last quarter. WINTON GROUP Ltd bought a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $5,673,000. Finally, Grandfield & Dodd LLC boosted its stake in shares of Regeneron Pharmaceuticals by 22.7% during the third quarter. Grandfield & Dodd LLC now owns 7,173 shares of the biopharmaceutical company’s stock valued at $2,898,000 after purchasing an additional 1,327 shares in the last quarter. Hedge funds and other institutional investors own 65.95% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Further Reading: What factors cause inflation to rise?

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply